Effects of amobarbital on heart protection during heart surgery
The Effect of Amobarbital on Myocardial Protection and Prognosis in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass
This study is testing if giving amobarbital during heart surgery can help protect the heart and improve recovery for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06757868 on ClinicalTrials.gov |
What this trial studies
This study explores the effects of amobarbital, a short-acting drug, on myocardial protection and prognosis in patients undergoing cardiac surgery with cardiopulmonary bypass. The research aims to investigate the new usage of this old drug and provide a reliable clinical basis for its potential value in improving treatment outcomes. Participants will receive amobarbital alongside midazolam during their surgery, and the study will assess the drug's impact on heart function and recovery.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 who are undergoing elective cardiac surgery with cardiopulmonary bypass.
Not a fit: Patients with severe liver or kidney dysfunction, or those with a history of drug abuse, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved heart protection strategies during cardiac surgeries, enhancing patient recovery and outcomes.
How similar studies have performed: While the use of amobarbital in this context is novel, previous studies on myocardial protection during cardiac surgery have shown varying degrees of success with different approaches.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age range: 18-65 years old, undergo elective cardiac surgery with extracorporeal circulation. * ASA II-III; * surgical duration is 3-6 hours; * Sign the informed consent form Exclusion Criteria: * BMI less than 18 kg/m2 or greater than 30 kg/m2; * Individuals with a history or potential history of drug abuse or alcohol dependence; * Preoperative use of sedatives or analgesics; * Individuals with severe liver and kidney dysfunction; * Individuals who are allergic or potentially allergic to barbiturates; * Patients with coagulation dysfunction, endocrine disorders, or other conditions that affect hemodynamic status; * Participated in other clinical studies in the past 3 months; * The researchers believe that participants who are not suitable to participate in this study.
Where this trial is running
Wuhan, Hubei
- Tongji hospital — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: mujun chang, Dr
- Email: changmujun@hotmail.com
- Phone: +862783663625
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.